Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

What happened with Novo Nordisk stock? On Dec. 20, Novo announced results from a phase 3 clinical trial surrounding one of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...

Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental ...

Investing.com -- Novo Nordisk (CSE: NOVOb ) shares jumped over 9% on Monday, despite the company’s disappointing results for ...

Novo Nordisk (NVO) and Eli Lilly (LLY), the undisputed ... disappointed investors with its next-gen weight loss candidate, CagriSema. The contrasting performances underscored the lofty ...

Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in response to this news. The drug-maker’s own target was higher and market ...